What are the limitations of clinical trials for the symptomatic treatment of amyotrophic lateral sclerosis (ALS)?

Updated: Jan 02, 2020
  • Author: Divakara Kedlaya, MBBS; Chief Editor: Ryan O Stephenson, DO  more...
  • Print


A study by Ng et al reported that Cochrane systematic reviews on symptomatic treatments for ALS/MND have not found robust evidence regarding management of ALS/MND symptoms. They also conclude, however, that rather than an actual lack of efficacy, clinical trials may not show benefit from an intervention owing to other factors, such as insufficient statistical power, wrong dose choice, insensitive outcome measures, or inappropriate eligibility of participants. Moreover, the generally small size of the trials meant that adverse treatment effects could not be reliably assessed. [6]

Also see the following:

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!